Table 1.
Cross-sectional demographics and clinical characteristics of the studied population based on Aβ+/Aβ− groups
| Aβ+ (n=50) | Aβ− (n=50) | p | |
|---|---|---|---|
| Aβ level (mean, SD) | 706.0 (174.36) | >1700 | |
| Sex (male/female) | 33/17 | 29/21 | 0.41 |
| BMI (mean, SD) | 26.07 (3.95) | 25.17 (3.44) | 0.225 |
| Age (years, mean, SD) | 73.40 (4.72) | 71.88 (4.45) | 0.101 |
| APOE ε4 carrier (n, %) | 25 (50%) | 7 (14.6%) | 0.003 |
| MMSE (mean, SD) | 28.60 (1.41) | 28.82 (1.37) | 0.431 |
| CDR (mean, SD) | 0 (0) | 0 (0) | |
| GFAP pg/mL (mean, SD) |
N=50 195.1 ± 87.13 |
N=50 134.0 ± 50.71 |
<0.001 |
| YKL-40 pg/mL (mean, SD) |
N=49 54,662.3 ± 39,697.31 |
N=49 82,947.1 ± 83,418.38 |
0.397 |
| MCP-1 pg/mL (mean, SD) |
N=50 91.74 ± 16.72 |
N=50 97.98 ± 34.01 |
0.358 |
| Eotaxin-1 pg/mL (mean, SD) |
N=50 195.0 ± 57.87 |
N=50 204.0 ± 94.80 |
0.783 |
P values in bold font were considered significant (p<0.05). Independent T-test and Pearson chi-square test were applied as appropriate